Combined >800 academic publications and >120 years of experience in clinical research, drug development, and clinical technologies.
Eirini Schlosser is a serial entrepreneur with experience building and leading data science and A.I. applications. After executing on > $60 Billion deal value in technology, healthcare, and consumer transactions as a member of Morgan Stanley’s Mergers & Acquisitions Execution Team, Eirini successfully transitioned from finance to technology where she spent the last 7 years developing, coding, and designing technologies as well as advising and investing other start-ups. She holds professional certifications in machine learning from MIT and a Masters from London Business School.
” I co-founded Dyania Health with the vision to be what the name means: Genius. Genius means we focus on the future. The future of healthcare is defined by new therapeutic innovations and how we get those innovations to the right patients, with specific conditions, for the best patient outcomes. Building a health genius requires us to extract sparks of knowledge and experience from each expert on our team and connect the dots to engineer solutions to big medical problems. I’m excited that we have the opportunity every day to play an integral role in the process to bring new therapeutics to patients with life threatening diseases. “
Dr. Iliopoulos was Assistant Professor of Microbiology & Immunology at Harvard Medical School, Associate Professor of Medicine at UCLA David Geffen School of Medicine and Founder/Director of the UCLA Center for Systems Biomedicine. Leads biomedical data research efforts in Dyania Health for different human diseases, including autoimmune and infectious diseases. He is an expert on identification and development of novel therapeutics using artificial intelligence methods. He has an extensive publication record and awards related to the pathobiology and development of therapeutics for inflammatory diseases. MIT certified on artificial intelligence.
Leads all the engineering, product development and technology research efforts at Dyania Health. A former space scientist who played a leading role in India’s maiden Mars mission at ISRO, Ankit has engineered multiple SAAS products which have been globally acclaimed. Ankit has extensive experience in building world class engineering teams for multiple startups across the world with engineers focussed on best practices, scalability and security across various software engineering domains. Ankit has over 10 years of experience in Software development across Web, Mobile, Distributed Systems, Machine Learning, NLP, Cryptocurrency, FinTech, Cyber Security and E-commerce.
” The technology that Dyania is trying to build will help Clinical Trials speed up and eventually, we will have life saving drugs shipped out quickly. It’s as simple as that but to be a part of the team which will have a huge impact in saving lives of so many people is something that excites me the most. “
Dr. Drakaki is an Assistant Professor of Hematology/Oncology and Urology, Medical Director of the Genitourinary Oncology Program and co-Director of Clinical Trial Research at the Institute of Urologic Oncology at UCLA. She is an expert on designing and running oncology clinical trials. She performed her hematology/oncology fellowship at Beth Israel Deaconess Medical Center at Harvard Medical School and her residency in internal medicine at Tufts University.
Dr Drakaki is the Principal investigator on multiple phase I-III clinical research studies for genitourinary cancers.Leading an innovative phase I study treating patients who have metastatic renal cell carcinoma with autologous dendritic cells transduced with AdGMCA9 (Kite Pharma, a Gilead Company).
Chair of the UCLA IRB Committee and thought leader in the field of cancer immunotherapy and co-founder of Kite Pharma. Expert in clinical trial design and involved in the keynote study showing efficacy of sunitinib (Pfizer) in patients with renal cell carcinoma.
Extensive experience on clinical trials design, performance and regulatory affairs. Allan is the executive chair of the UCLA IRB Committee, Professor of Urology at the David Geffen School of Medicine at UCLA and Vice Chair of Academic Affairs for the Department of Urology, Executive Chair of the UCLA IRB, a member of the Executive Committee of the Institute of Urologic Oncology. Allan performed his urology/oncology fellowship at UCLA School of Medicine and holds an MD degree from Robert Wood Johnson Medical School.
Professor Athanasios Papatsoris holds two MSc and PhD with a 2-year Endourology/Laparoscopy fellowship in London and Le Mans. He has an honorary contract with Addenbrooke’s Hospital, Cambridge and he is a faculty member of Cambridge Medical Academy. He is the v. Chairman of the EBU Examination Committee. He is Professor of Urology of the National and Kapodistrian University of Athens at the 2nd University Department of Urology, Sismanoglio. General Hospital, Athens Greece.
He is on the Board of HUA, IMBE and HGUCG. His H-Index is 38 with more than 203 publications in PubMed and with more than 4100 citations. Recently he received the “Arthur Smith” award.
World expert on clinical trial design and performance of bladder cancer phase I-III clinical trials.Identified that avelumab (Pfizer, Merck KGaA) plus best supportive care significantly prolonged overall survival among patients with urothelial cancer.Dr. Petros Grivas is board-certified medical oncologist with expertise in genitourinary (GU) cancers. He is the Clinical Director of the GU cancers Program at University of Washington and Associate Professor (Dept of Medicine, Division of Oncology). He received M.D. and Ph.D. in Greece in 2005 and 2009, respectively. He completed Internal Medicine Residency at Hahnemann University Hospital/Drexel University College of Medicine (Philadelphia) in 2010, and Hematology/Oncology Fellowship at University of Michigan (Ann Arbor) in 2013. He was Clinical Lecturer before he was recruited as Assistant Professor at Cleveland Clinic (Cleveland). He had main role in clinical trials leading to FDA approval of new drugs for bladder/urothelial cancer.
Brian Dolan is well-known in the data community as a leading mathematician, data scientist and cyberneticist with more than 20 years of hands-on experience. Prior to starting Verdant AI, Brian co-founded Deep 6 AI, Qurius Inc and Discovix. Brian has consulted and led enterprise analytic projects from design to implementation for clients like EMC, SuperValu, Northern Trust, Zions National Bank, Havas Media, T-Mobile, the U.S. Intelligence Community, and Research In Motion. Formerly Chief Scientist at Greenplum (acquired by EMC), Brian also headed up data scientist teams at Yahoo! Inc. and served as Director of Research Analytics at FOX/MySpace. Throughout his career, he has developed thousands of machine learning products, and his consulting experience includes numerous state and local governments. He is also co-author of the seminal “MAD Skills: New Analysis Practices for Big Data,” which has been cited more than 400 times in the big data/machine learning industry. In 2017 Brian spoke at TEDx Millsaps College on A Cybernetic View of AI in HealthCare Systems. Most recently, he has written a chapter entitled “Information Pathways: From Natural to Artificial Systems, and Back Again” in the book Transforming Healthcare with Big Data and AI, to be published in 2019. Brian has a Master of Arts in Pure Mathematics from UCLA as well as a Master of Science in Bio-Mathematics from the David Geffen School of Medicine.
Panos Zoubourlis finished his medical degree at the National and Kapodistrian University of Athens with high honors and a GPA of 8.7/10. He proceeded to score above the 95th percentile on the USMLE Step 1 Boards and completed a clinical elective program at John Hopkins Medical School in the hematology oncology department. He has been published as primary author on the research article titled ”Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn’t, and What the Future Holds” and has been subsequent author in 4 other publications focused on the fields of oncology, gynecology, and cardiology. Panos brings a mathematical approach to clinical technology applications, which allows the team to build computational models around clinical characteristics. He uniquely combines skills in coding with medical knowledge to bridge multidisciplinary teams that come from pure engineering and clinician backgrounds. As such, he has made himself an invaluable pillar to the growth and implementation of Dyania Health’s vision.
Helaine Catalano brings 30 years of experience as a Human Resource Executive, providing organizational leadership coaching and development to accelerate performance and productivity of individuals and teams. A former Executive of Johnson & Johnson, she was most recently Vice President of Human Resources, Global Franchises and Functions for the Consumer Products Company. She was instrumental in driving employee engagement programs for high performance work environments.
Dino has 20+ years of experience in sales, finance, and accounting. He has worked for both Fortune 500 and start-up companies in various finance and accounting roles, while also maintaining key relationships with top 10 CRO’s. Dino holds an MBA from USC with a concentration in Finance.
Konstantinos studied Art & Design at University of Sunderland, Great Britain specialising in Graphic Design. For the past 15 years he has continuously worked as a freelance designer on numerous design projects. His focus is on the design of web sites, Branding Identities and UI/UX Design.
Aditya has been a specialized Full Stack Developer since 2019 and deeply believes in the Mission of Dyania. His contribution in the past year to the front-end development of our software has been rewarding, especially when the team finds solutions to challenging issues. When not coding, Aditya enjoys e-sports and and solving complex problems.
Armaan is an electrical engineer by education, a software developer by profession, and a designer by passion. Over 5 years of experience in developing enterprise software spanning across various domains. At Dyania, he has the unique privilege of indulging into incorporating cutting edge technology into the product in an age old domain and exploring the opportunities Natural Language Processing can offer to streamlining the clinical trial recruitment space. Armaan loves going on long rides and is an automobile enthusiast!